Shares of Insulet Co. (NASDAQ:PODD) have been assigned an average rating of “Buy” from the twenty analysts that are presently covering the stock, MarketBeat Ratings reports. Eight equities research analysts have rated the stock with a hold recommendation and twelve have assigned a buy recommendation to the company. The average 1 year price objective among brokerages that have issued ratings on the stock in the last year is $64.42.

PODD has been the topic of several research reports. Barclays reaffirmed a “buy” rating and set a $78.00 price target on shares of Insulet in a research note on Wednesday, December 13th. Jefferies Group upped their price target on Insulet from $58.00 to $67.00 and gave the company a “buy” rating in a research note on Friday, November 3rd. Canaccord Genuity raised Insulet from a “hold” rating to a “buy” rating and upped their price target for the company from $50.00 to $65.00 in a research note on Wednesday, November 1st. Morgan Stanley upped their price target on Insulet from $55.00 to $63.00 and gave the company an “equal weight” rating in a research note on Friday, November 3rd. Finally, Zacks Investment Research lowered Insulet from a “buy” rating to a “hold” rating in a research note on Saturday, November 11th.

Insulet (PODD) traded down $1.01 during trading on Tuesday, reaching $72.46. The company’s stock had a trading volume of 466,611 shares, compared to its average volume of 537,257. The company has a current ratio of 4.88, a quick ratio of 4.42 and a debt-to-equity ratio of 4.65. The firm has a market capitalization of $4,233.16, a price-to-earnings ratio of -144.92 and a beta of 1.59. Insulet has a one year low of $38.43 and a one year high of $78.65.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Cerebellum GP LLC bought a new stake in Insulet in the fourth quarter valued at about $122,000. Equitec Specialists LLC bought a new stake in Insulet in the fourth quarter valued at about $145,000. James Hambro & Partners bought a new stake in Insulet in the fourth quarter valued at about $165,000. C M Bidwell & Associates Ltd. bought a new stake in Insulet in the fourth quarter valued at about $188,000. Finally, Diversified Trust Co bought a new stake in Insulet in the fourth quarter valued at about $218,000.

TRADEMARK VIOLATION NOTICE: “Insulet Co. (PODD) Receives Consensus Recommendation of “Buy” from Analysts” was first published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this news story on another website, it was stolen and reposted in violation of U.S. and international trademark and copyright law. The legal version of this news story can be read at https://www.thecerbatgem.com/2018/02/13/insulet-co-podd-receives-consensus-recommendation-of-buy-from-analysts.html.

Insulet Company Profile

Insulet Corporation is engaged in the development, manufacturing and sale of the OmniPod Insulin Management System (the OmniPod System), an insulin delivery system for people with insulin-dependent diabetes. The Omnipod System features a self-adhesive disposable tubeless Omnipod device, which is worn on the body for approximately three days at a time and its wireless companion, the handheld Personal Diabetes Manager (PDM).

Analyst Recommendations for Insulet (NASDAQ:PODD)

Receive News & Ratings for Insulet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insulet and related companies with MarketBeat.com's FREE daily email newsletter.